A trial of topiramate for patients with hereditary spinocerebellar ataxia-Reference-Cited by-同舟云学术

A trial of topiramate for patients with hereditary spinocerebellar ataxia

Published:2023-02 Issue:2 Volume:11 Page:
ISSN:2050-0904
Container-title:Clinical Case Reports
language:en
Short-container-title:Clinical Case Reports

Author:

Miura Shiroh¹^ORCID,Sawada Ryusuke²,Yorita Akiko³,Kida Hiroshi⁴,Kamada Takashi⁵,Yamanishi Yoshihiro⁶

Affiliation:

1. Department of Neurology and Geriatric Medicine Ehime University Graduate School of Medicine Toon Ehime Japan

2. Department of Pharmacology Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Kita‐ku Okayama Japan

3. Division of Respirology, Neurology and Rheumatology, Department of Medicine Kurume University School of Medicine Kurume Fukuoka Japan

4. Department of Anatomy Fukuoka University School of Medicine Jonan‐ku Fukuoka Japan

5. Department of Neurology Fukuoka Sanno Hospital Sawara‐ku Fukuoka Japan

6. Department of Bioscience and Bioinformatics, Faculty of Computer Science and Systems Engineering Kyushu Institute of Technology Iizuka Fukuoka Japan

Abstract

AbstractIn an open pilot trial, six patients with various hereditary forms of spinocerebellar ataxia (SCA) were assigned to topiramate (50 mg/day) for 24 weeks. Four patients completed the protocol without adverse events. Of these four patients, topiramate was effective for three patients. Some patients with SCA could respond to treatment with topiramate.

Publisher

Wiley

Subject

General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ccr3.6980

Reference24 articles.

1. Hereditary ataxias: overview

2. EFNS/ENS Consensus on the diagnosis and management of chronic ataxias in adulthood

3. Drug repositioning: identifying and developing new uses for existing drugs

4. New uses for old drugs

5. Challenges and opportunities of drug repositioning